Nigel Temperton

ORCID iD
orcid.org/0000-0002-7978-3815
  • Country
  • Show details Hide details
United Kingdom

Sources:
Nigel Temperton (2016-01-24)

  • Websites
  • Show details Hide details
Linked In profile

Sources:
Nigel Temperton (2016-01-07)

Staff web page

Sources:
Nigel Temperton (2016-01-07)

Lab web page

Sources:
Nigel Temperton (2016-01-07)

  • Other IDs
  • Show details Hide details
Scopus Author ID: 6506235116

Sources:
Scopus to ORCID (2013-07-03)

ResearcherID: K-5158-2013

Sources:
0000-0002-7978-3815 (2013-10-06)

Loop profile: 185243

Sources:
Loop (2016-01-07)

Biography

Nigel obtained his BSc in Microbiology and Genetics from University College London (UCL) in 1990 and an MSc in Applied Molecular Biology of Infectious Diseases (1992), PhD in Molecular Parasitology (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). Post PhD, Nigel returned to UCL as a post-doctoral scientist at the Centre for Virology (Royal Free Campus). In 2003 Nigel transferred to the MRC/UCL Centre for Medical Molecular Virology as a senior post-doctoral scientist and subsequently as Principal Investigator, funded by the MRC and industry. He is currently Senior Lecturer/Associate Professor in Biological Sciences at the School of Pharmacy, University of Kent, and joint director of the Viral Pseudotype Unit (VPU). Nigel is a Fellow of the Royal Society of Biology and Senior Associate Member of the Royal Society of Medicine (RSM). In 2009 Nigel was elected as a member of the highly prestigious Medical Research Club, London. Nigel’s research interests lie primarily in the control of emerging/re-emerging and transboundary viruses (pandemic/inter-pandemic influenza, MERS/SARS coronavirus, rabies/lyssavirus and Ebolavirus) for which he has pioneered the development and deployment of viral pseudotype-based serologic and pharmacologic assays. Nigel co-established the VPU in 2010 to act as an interface between academia, industry, animal and public health laboratories with the purpose of translating basic virus research into in vitro cell culture based assays that can be readily employed for the characterization of vaccines, antivirals and therapeutic antibodies. Nigel is an advocate of using social media platforms and new Open Access/Open Data initiatives for the dissemination of VPU activities.
  • : , ,

    {{group.getActive().startDate.year}}-{{group.getActive().startDate.month}} to present {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}}
     ()
    Source: {{(group.getActive().sourceName == null || group.getActive().sourceName == '') ? group.getActive().source : group.getActive().sourceName}}
    Created:
No education added yet
  • : , ,

    {{group.getActive().startDate.year}}-{{group.getActive().startDate.month}} to present {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}} {{group.getActive().endDate.year}}-{{group.getActive().endDate.month}}-{{group.getActive().endDate.day}}
     ()
    Source: {{(group.getActive().sourceName == null || group.getActive().sourceName == '') ? group.getActive().source : group.getActive().sourceName}}
    Created:
No employment added yet
No Funding added yet
No publications added yet